Literature DB >> 22275378

Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.

Jeffrey A Bakal1, Cynthia M Westerhout2, Paul W Armstrong2.   

Abstract

Composite endpoints are commonly used in cardiovascular clinical trials. When using a composite endpoint a subject is considered to have an event when the first component endpoint has occurred. The use of composite endpoints offers the ability to incorporate several clinically important endpoint events thereby augmenting the event rate and increasing statistical power for a given sample size. One assumption of the composite is that all component events are of equal clinical importance. This assumption is rarely achieved given the diversity of component endpoints included. One means of adjusting for this diversity is to adjust the outcomes using severity weights determined a priori. The use of a weighted endpoint also allows for the incorporation of multiple endpoints per patient. Although weighting the outcomes lowers the effective number of events, it offers additional information that reduces the variance of the estimate. We created a series of simulation studies to examine the effect on power as the individual components of a typical composite were changed. In one study, we noted that the weighted composite was able to offer discriminative power when the component outcomes were altered, while the traditional method was not. In the other study, we noted that the weighted composite offered a similar level of power to the traditional composite when the change was driven by the more severe endpoints.
© The Author(s) 2011.

Entities:  

Keywords:  Trial design; cardiovascular; composite endpoint

Mesh:

Year:  2012        PMID: 22275378     DOI: 10.1177/0962280211436004

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  16 in total

1.  Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.

Authors:  Ionut Bebu; John M Lachin
Journal:  Biostatistics       Date:  2015-09-08       Impact factor: 5.899

2.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

3.  Statistical models for composite endpoints of death and non-fatal events: a review.

Authors:  Lu Mao; KyungMann Kim
Journal:  Stat Biopharm Res       Date:  2021-07-06       Impact factor: 1.586

4.  A composite outcome for neonatal cardiac surgery research.

Authors:  Ryan J Butts; Mark A Scheurer; Sinai C Zyblewski; Amy E Wahlquist; Paul J Nietert; Scott M Bradley; Andrew M Atz; Eric M Graham
Journal:  J Thorac Cardiovasc Surg       Date:  2013-04-12       Impact factor: 5.209

5.  Application of the Wei-Lachin multivariate one-directional test to multiple event-time outcomes.

Authors:  John M Lachin; Ionut Bebu
Journal:  Clin Trials       Date:  2015-09-02       Impact factor: 2.486

6.  Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.

Authors:  Sumeet Subherwal; Kevin J Anstrom; William S Jones; Michael G Felker; Sanjay Misra; Michael S Conte; William R Hiatt; Manesh R Patel
Journal:  Am Heart J       Date:  2012-09       Impact factor: 4.749

7.  Multistate modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation to inform drug development.

Authors:  David A James; Jennifer Ng; Jiawei Wei; Marc Vandemeulebroecke
Journal:  Biom J       Date:  2018-09-17       Impact factor: 2.207

8.  Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women.

Authors:  Grace Montepiedra; Soyeon Kim; Adriana Weinberg; Gerhard Theron; Timothy R Sterling; Sylvia M LaCourse; Sarah Bradford; Nahida Chakhtoura; Patrick Jean-Philippe; Scott Evans; Amita Gupta
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

9.  A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.

Authors:  Grace Montepiedra; Ritesh Ramchandani; Sachiko Miyahara; Soyeon Kim
Journal:  Stat Med       Date:  2020-10-26       Impact factor: 2.373

Review 10.  Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Haesook T Kim; Brent Logan; Daniel J Weisdorf
Journal:  Transplant Cell Ther       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.